B-amyloid as a Marker for GBM Bioimaging - Trial NCT05820191
Access comprehensive clinical trial information for NCT05820191 through Pure Global AI's free database. This Phase 2 trial is sponsored by Universidad Central del Caribe and is currently Not yet recruiting. The study focuses on Glioblastoma. Target enrollment is 3 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Universidad Central del Caribe
Timeline & Enrollment
Phase 2
Jul 01, 2023
Jul 01, 2024
Primary Outcome
Measurement of Amyvid deposition in GBM tumor structures,Correlation of Amyvid deposition with components of high metabolic activity.,Correlation of Amyvid deposition with components of increased vascularization.
Summary
This project is aimed at improvement of glioblastoma (GBM) diagnostic strategies for
 discrimination of tumor progression and chemo- and radiotherapeutic treatment-related changes
 in brain tissue. The study will elucidate the diagnostic value of PET imaging with use of
 amyloid-ฮฒ radioisotope tracer Amyvid (Florbetapir F18) for GBM. The results of the study will
 provide data for development of new approach for GBM diagnostics.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05820191
Non-Device Trial